Circulating adrenomedullin estimates survival and reversibility of organ failure in sepsis: the prospective observational multinational Adrenomedullin and Outcome in Sepsis and Septic Shock-1 (AdrenOSS-1) study

What Was Tested

This observational study looks at Adrenomedullin.

Adrenomedullin (ADM) regulates vascular tone and endothelial permeability during sepsis.

Levels of circulating biologically active ADM (bio-ADM) show an inverse relationship with blood pressure and a direct relationship with vasopressor requirement.

Who Took Part

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

Secondary outcomes included organ failure as defined by Sequential Organ Failure Assessment (SOFA) score, organ support with focus on vasopressor/inotropic use, and need for renal replacement therapy.

AdrenOSS-1 included 583 patients admitted to the ICU with sepsis or septic shock.

How the Study Was Run

In design terms this was a randomized study.

The participants were allocated by chance, so the Adrenomedullin group and the comparison group should start out alike.

AdrenOSS-1 was a prospective observational multinational study.

The primary outcome was 28-day mortality.

What Was Measured

Levels of circulating biologically active ADM (bio-ADM) show an inverse relationship with blood pressure and a direct relationship with vasopressor requirement.

In the present prospective observational multinational Adrenomedullin and Outcome in Sepsis and Septic Shock 1 (, AdrenOSS-1) study, the researchers assessed relationships between circulating bio-ADM during the initial intensive care unit (ICU) stay and short-term outcome in order to eventually design a biomarker-guided randomized controlled trial.

The subject headings attached to it are Adrenomedullin, Belgium, Biomarkers, Chi-Square Distribution, France, Germany and Hospital Mortality.

The authors tagged it with the keywords Outcome, Sepsis-2 and Sepsis-3.

What This Means in Plain Language

The paper is a randomized study of Adrenomedullin.

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2018 (Critical care (London, England)), a journal based in England.

More context: the Adrenomedullin compound page, all human trials.